Literature DB >> 19513765

Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.

Philipp Stockmann1, Fabian M Hinkmann, Michael M Lell, Matthias Fenner, Eleftherios Vairaktaris, Friedrich-Wilhelm Neukam, Emeka Nkenke.   

Abstract

It was the aim of the present study to find out which radiological imaging techniques allow assessing the extent of bisphosphonate-associated osteonecrosis of the jaw (BONJ) in an adequate way. Twenty-four patients suffering from BONJ were included in the study. Before surgery, each patient was examined with panoramic radiograph, contrast-enhanced magnetic resonance imaging (MRI) and non-enhanced computed tomography. The detectability of BONJ was assessed for the three imaging techniques. The extent of the jaw region affected by BONJ was determined in MRI and CT scans and compared to the intra-operative situation. The detectability of BONJ lesions was 54% for panoramic radiographs, 92% for MRI scans and 96% for computed tomography (CT) scans. The intra-operatively assessed extent of BONJ correlated significantly with the measurements on CT scans (p = 0.0004) but did not correlate significantly with the measurements in MRI scans (p = 0.241). The intra-operatively measured extent of BONJ differed significantly from the CT measurements (p = 0.00003) but not from the MRI data (p = 0.137). Although MRI as well as CT have a high detectability for BONJ lesions that exceeds that of panoramic radiographs by far, both techniques show problems with the exact assessment of the extent of BONJ lesions in the individual patients. Therefore, the relevance of MRI and CT for the preoperative assessment of the extent of BONJ lesions is limited. Future research should focus on the identification of imaging techniques that allow assessing the extent of BONJ lesions with a higher accuracy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513765     DOI: 10.1007/s00784-009-0293-1

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  14 in total

1.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

Authors: 
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

2.  Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.

Authors:  S Chiandussi; M Biasotto; F Dore; F Cavalli; M A Cova; R Di Lenarda
Journal:  Dentomaxillofac Radiol       Date:  2006-07       Impact factor: 2.419

3.  [A proposed algorithm for medicodental care of patients treated with bisphosphonates].

Authors:  M Hugentobler; M Richter
Journal:  Rev Stomatol Chir Maxillofac       Date:  2006-12

4.  [Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases].

Authors:  Knut A Grötz; Christian Walter; Christian Küttner; Bilal Al-Nawas
Journal:  Strahlenther Onkol       Date:  2007-04       Impact factor: 3.621

Review 5.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

6.  Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.

Authors:  Alberto Bedogni; Stella Blandamura; Zerina Lokmic; Carla Palumbo; Mirko Ragazzo; Francesca Ferrari; Alberto Tregnaghi; Francesco Pietrogrande; Olindo Procopio; Giorgia Saia; Marzia Ferretti; Giorgio Bedogni; Luigi Chiarini; Giuseppe Ferronato; Vito Ninfo; Lucio Lo Russo; Lorenzo Lo Muzio; Pier Francesco Nocini
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2008-03

7.  Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.

Authors:  Gregg S Wilkinson; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  J Natl Cancer Inst       Date:  2007-06-27       Impact factor: 13.506

8.  Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer.

Authors:  Silvio Diego Bianchi; Matteo Scoletta; Francesca Bozzalla Cassione; Giuseppe Migliaretti; Marco Mozzati
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2007-06-07

9.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

10.  Treatment results of bisphosphonate-related osteonecrosis of the jaws.

Authors:  Arno Wutzl; Edwin Biedermann; Felix Wanschitz; Rudolf Seemann; Clemens Klug; Arnulf Baumann; Franz Watzinger; Kurt Schicho; Rolf Ewers; Gabriele Millesi
Journal:  Head Neck       Date:  2008-09       Impact factor: 3.147

View more
  33 in total

1.  Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws.

Authors:  Thomas Mücke; Janett Koschinski; Herbert Deppe; Stefan Wagenpfeil; Christoph Pautke; David A Mitchell; Klaus-Dietrich Wolff; Frank Hölzle
Journal:  J Cancer Res Clin Oncol       Date:  2010-10-07       Impact factor: 4.553

Review 2.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

Review 3.  Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.

Authors:  Valesca Sander Koth; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

4.  Cone beam computed tomography for diagnosis of bisphosphonate-related osteonecrosis of the jaw: evaluation of quantitative and qualitative image parameters.

Authors:  Roman Guggenberger; Emrah Koral; Wolfgang Zemann; Christine Jacobsen; Gustav Andreisek; Philipp Metzler
Journal:  Skeletal Radiol       Date:  2014-07-05       Impact factor: 2.199

5.  Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?

Authors:  Christoph Klingelhöffer; Manja Klingelhöffer; Steffen Müller; Tobias Ettl; Ulrich Wahlmann
Journal:  Dentomaxillofac Radiol       Date:  2016-05-23       Impact factor: 2.419

6.  CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.

Authors:  Akira Baba; Tazuko K Goto; Hiroya Ojiri; Mutsumi Takagiwa; Chiho Hiraga; Masahiro Okamura; Sho Hasegawa; Yumi Okuyama; Nobuhiro Ogino; Hideomi Yamauchi; Yuko Kobashi; Shinji Yamazoe; Yohei Munetomo; Takuji Mogami; Takeshi Nomura
Journal:  Dentomaxillofac Radiol       Date:  2018-02-13       Impact factor: 2.419

7.  Meaning and Limitation of Cortical Bone Width Measurement with DentaScan in Medication-Related Osteonecrosis of the Jaws.

Authors:  Eiji Iwata; Masaya Akashi; Megumi Kishimoto; Junya Kusumoto; Takumi Hasegawa; Shungo Furudoi; Takahide Komori
Journal:  Kobe J Med Sci       Date:  2017-02-15

8.  The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy.

Authors:  Satish K S Kumar; Amita Gorur; Christoph Schaudinn; Charles F Shuler; J William Costerton; Parish P Sedghizadeh
Journal:  Curr Osteoporos Rep       Date:  2010-03       Impact factor: 5.096

9.  Bisphosphonate-induced osteonecrosis of the jaw: comparison of disease extent on contrast-enhanced MR imaging, [18F] fluoride PET/CT, and conebeam CT imaging.

Authors:  R Guggenberger; D R Fischer; P Metzler; G Andreisek; D Nanz; C Jacobsen; D T Schmid
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

10.  Do γδ T cells predict osteonecrosis of the jaw?

Authors:  M Neale Weitzmann
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.